Why partner with AstraZeneca?
We have a global commercial presence and strength in emerging markets, particularly in China. Our innovative medicines, many of which are developed in partnership with others, are used by millions of patients worldwide.
$22.1bn
total revenue
$1bn
externalisation revenue
260+
major or strategically important deals in last 3 years
630+
collaborations worldwide help us access the best science, stimulate innovation and accelerate delivery of new medicines for unmet medical needs
64,600
employees
25
manufacturing sites in 16 countries
$5.9bn
invested in R&D
90%
of pipeline has a precision medicine approach
For year ending 31 December 2018
Pushing the boundaries of science to deliver life-changing medicines
Science is what drives AstraZeneca. We keep pushing the boundaries of science to deliver life-changing medicines that address significant unmet medical need in diseases affecting millions of people around the world.
Scientific capabilities
Our range of scientific capabilities spans biologics and small molecules, as well as new drug modalities. We are looking for new and emerging drug platforms that can revolutionise the treatment of diseases. Examples are in vivo biologics, novel bispecifics, and nanobots/smart drug-delivery systems.
Genomic and data science
We are also harnessing the growing potential of genomic and data science to increase our understanding of disease at the molecular level. This is opening the way to new therapeutic platforms and technologies, such as PROTACS, in vivo biologics, cell therapy, modulation of the microbiome, and tissue repair.
Encouraging innovation and inspiring the next generation of start-ups
Innovation in life sciences
Entrepreneurial thinking and smart risk-taking are at the heart of what we do at AstraZeneca. We are also passionate about supporting innovation in life sciences and helping the next generation of entrepreneurs succeed within our local bioscience ecoystems globally.
Business mentoring initiatives
In the UK, we have several business mentoring initiatives to support life science entrepreneurs. More than 80 AstraZeneca employees regularly share their expertise in areas such as business development, marketing, intellectual property and early development with the next generation of biotech start-ups. This includes programmes run by the University of Cambridge’s Judge Business School and Lucy Cavendish College, among others.
I•DREAM
I•DREAM is an external collaboration platform in R&D, education, technology and government affairs being implemented through local bio-hubs in our Emerging Markets. These bio-hubs improve local capacity for R&D to address local needs. In 2018, AstraZeneca launched iDREAM hubs in Russia, Brazil and Taiwan, with important collaboration agreements signed.
I•Campus
In China, we opened a new health innovation hub called I•Campus, in September 2019. A partnership with the Wuxi Government, I•Campus brings together innovative 4D (Drug, Device, Diagnosis and Digital) companies, government, medical and academic institutions via an open collaboration platform, helping to accelerate healthcare innovation and sciences in China.
Veeva ID: Z4-21504
Date of Prep: Dec 2019
Expiry Date: Dec 2020